CAMBRIDGE, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Targanta Therapeutics Corporation today announced its participation in the Massachusetts Biotechnology Council’s (MBC’s) annual MASS Opportunities Investment Conference, taking place November 8, 2007 at the Hilton Boston Logan Airport. Mark Leuchtenberger, President and Chief Executive Officer of Targanta, will be presenting at 11:45 am ET in New England Ballroom A.
The audio portion of the presentation will be webcast live and available for replay at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TARG&item_id=1683196, or through the Investor Relations section of Targanta’s website at www.targanta.com/investors.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company’s pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. To find out more about Targanta , visit our website at www.targanta.com.
CONTACT: Investors, George Eldridge, Senior Vice President Finance &
Administration and Chief Financial Officer of Targanta Therapeutics
Corporation, +1-617-577-9020 x222; or Financial media, Brian Ritchie of
Financial Dynamics, +1-212-850-5683, for Targanta Therapeutics Corporation
Web site: http://www.targanta.com/
